{"prompt": "['2016N298481_0', 'CONFIDENTIAL', '205270', '10.4.6.', 'Analysis of Patient-Reported Outcomes Measures and', 'Actigraphy', 'Analyses to compare the patient reported effects of daprodustat and placebo on', 'symptoms, severity, HR-QoL, and health status, as discussed in Section 9.6, will be', 'described in the RAP. Analyses regarding the effects of daprodustat and placebo on', 'physical activity and sleep measured by the actigraphy assessment as discussed in Section', '9.7 will also be described in the RAP.', '72']['2016N298481_02', 'CONFIDENTIAL', '205270', '11.', 'REFERENCES', '1. Bjorner J, Wallenstein G, Martin M, Lin P, Blaisdell-Gross B, Piech C, Mody S et', 'al. Interpreting score differences in the SF-36 Vitality scale: using clinical conditions', 'and functional outcomes to define the minimally important difference. Current', 'Medical Research and Opinion, 2007;23(4):731-739', '2. GlaxoSmithKline Document Number 2014N219818 00, GSK1278863, A 24-week,', 'Phase 2B, randomized, controlled, parallel-group,multi-cent study to evaluate the', 'safety and efficacy of GSK1278863 in subjects with anemia associated with', 'chronickidney disease who are not on dialysis. 13-JAN-2016', '3. GlaxoSmithKline Document Number 2015N230102 03, GSK1278863, A phase 3', 'randomized, open-label (sponsor-blind), active-controlled, parallel-group multi-', 'center, event driven study in non-dialysis subjects with anemia associated with', 'chronic kidney disease to evaluate the safety and efficacy of daprodustat compared', 'to darbepoetin alfa (ASCEND-ND). 12-OCT-2016', '4. GlaxoSmithKline Document Number RM2008/00267/07, Version 7 to GSK1278863', \"Investigator's Brochure, 14-OCT-2015.\", '5. Holdstock L, Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, et al.', 'Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor', 'GSK1278863 for Treatment of Anemia. J Am Soc Nephrol.2016;27(4):1234-44.', '6. KDIGO Clinical Practice Guidelines for Anemia in Chronic Kidney Disease. Kidney', 'int. 2012; 2(4).', 'http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGOAnemia%20GL.pdf', '7. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al;', 'CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A New Equation', 'to Estimate Glomerular Filtration Rate. Ann Intern Med 2009; 150(9):604-12.', '8. Martin M, Patrick D, Shravanthi G, Bennett A, Leidy N, Nissenson A, et al. Content', 'validation of two SF-36 subscales for use in type 2 diabetes and non-dialysis chronic', 'kidney disease-related anemia. Qual Life Res. 2011;20:889-901.', '9. Skali H, Lin J, Pfeffer MA, Chen CY, Cooper ME, McMurray JJ, et al. Hemoglobin', 'stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the', 'TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo', 'arm. Am J Kidney Dis. 2013;61(2):238-46.', '73']['2016N298481_02', 'CONFIDENTIAL', '205270', '12.', 'APPENDICES', '12.1.', 'Appendix 1: Abbreviations and Trademarks', 'Abbreviations', 'ADPKD', 'Autosomal dominant polycystic kidney disease', 'AE', 'Adverse event', 'ALT', 'Alanine transaminase', 'ANCOVA', 'Analysis of Covariance', 'ANSM', \"L'Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des\", 'produits de sant\u00e9', 'AST', 'Aspartate transaminase', 'BP', 'Blood pressure', 'CEC', 'Clinical Events Classification', 'CI', 'Confidence interval', 'CKD', 'Chronic kidney disease', 'CKD-AQ', 'Chronic Kidney Disease - Anemia Questionnaire', 'CKD-EPI', 'Chronic kidney disease Epidemiology Collaboration', 'CNIL', \"Commission Nationale de l'Informatique et des Libert\u00e9s\", 'CPK', 'Creatine phosphokinase', 'CRA', 'Clinical Research Assistant', 'CTR', 'Clinical Trials Register', 'CT', 'Computed tomography', 'CV', 'Cardiovascular', 'DBP', 'Diastolic blood pressure', 'ECG', 'Electrocardiogram', 'eCRF', 'Electronic case report form', 'eGFR', 'Estimated glomerular filtration rate', 'EP', 'Evaluation period', 'EPO', 'Erythropoietin', 'EQ-5D-5L', 'EuroQol 5 Dimension 5 Level Health Utility Index', 'EQ-VAS', 'EuroQol Visual Analogue Scale', 'ESA', 'Erythropoetin-stimulating agent', 'FDA', 'Food and Drug Administration', 'FRP', 'Females of reproductive potential', 'FSH', 'Follicle stimulating hormone', 'GCP', 'Good Clinical Practice', 'GI', 'Gastrointestinal', 'GSK', 'GlaxoSmithKline', 'hCG', 'Human chorionic gonadotrophin', 'HD', 'Hemodialysis', 'HDL-c', 'High density lipoprotein-C', 'HDPE', 'High density polyethylene', 'Hgb', 'Hemoglobin', 'HIF', 'Hypoxia-inducible factor', '74']\n\n###\n\n", "completion": "END"}